A Non-interventional, Multicentre Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Ovarian Cancer
- Sponsor
- AstraZeneca
- Enrollment
- 240
- Locations
- 1
- Primary Endpoint
- BRCA1 or BRCA2 mutation positive status
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This is a non-interventional, cross-sectional, multicentre, observational study planned to be conducted at 15 sites across all geographical regions of India. The study targets to enrol 240 patients with approximately 16 patients from each site. Written approval of Independent Ethics Committee (IEC)/ Institutional Review Board (IRB) and written informed consent from willing patients will be obtained prior to the start of the study.
Detailed Description
This is a non-interventional, cross-sectional, multicentre, observational study to be conducted at 15 sites from different geographical regions across India. The study targets to enrol 240 patients with nearly 16 patients per site over 6 months. The study will enrol females with diagnosis of ovarian, primary peritoneal, or fallopian tube cancer. No study medication will be prescribed or administered as a part of study procedure. The study will start only after obtaining written approval of Independent Ethics Committee (IEC) / Institutional Review Board (IRB) and written informed consent of the patient. The study will start only after obtaining written approval of Independent Ethics Committee (IEC) / Institutional Review Board (IRB) and written informed consent of the patient. Eligible patients will undergo physical examination and data of demographics, vital signs, present/ past history of illness, family history of breast/ovarian cancer, current and previous chemotherapy regimen and current medication will be collected.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who provide written informed consent
- •Female ≥ 18 years of age
- •Previously or newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer patients.
Exclusion Criteria
- •Patient with any medical condition that, in the opinion of the investigator, would interfere with safe completion of the study
Outcomes
Primary Outcomes
BRCA1 or BRCA2 mutation positive status
Time Frame: 1 day
ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles)
Secondary Outcomes
- Association between histopathological type and BRCA 1/BRCA 2 mutation positive status(1 Day)